Camonsertib

3 trials 1 recruiting

Filter these 3 trials by condition, phase, country and more.

Open in Search →

3 Registered trials

1 Recruiting

2 Completed trials

2 Sponsors

9 Countries

Phase II

Phase I/II

Phase I

Phase II: 1 Phase I/II: 1 Phase I: 1

Oversight events:

1 urgent safety measure across 1 trial

View oversight register →

Indications tested

Non-small cell lung cancer metastatic 1

Sponsors using this IMP

F. Hoffmann-La Roche AG 2 Debiopharm International S.A. 1

All trials

3 total

A phase 1 trial to study how safe and tolerable Lunresertib is, alone or in Combination with RP-3500 or Debio 0123, when administered in pat… Recruiting

2023-510063-35-00 Phase I 3 countries Debiopharm International S.A.
Tumor-Agnostic Precision Immuno-Oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study Ended

2023-507418-28-00 Phase II 8 countries F. Hoffmann-La Roche AG
A Study to Evaluate Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients with Metastatic Non-Small Cell Lu… Ended

2023-504038-23-00 Phase I/II 2 countries F. Hoffmann-La Roche AG

Showing 1–3 of 3 trials

← All drugs A–Z